Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affymax $50M offering, as Hematide still on track for Q2 US filing

This article was originally published in Scrip

Executive Summary

The biopharmaceutical company Affymax is trying to raise $50 million through a secondary public offering in order to support development and marketing of its investigational erythropoiesis-stimulating agent (ESA), Hematide (peginesatide). The compound is partnered with Takeda, and following a meeting the two companies had in November with the US FDA, they believe that data from the completed trials of the compound are sufficient for an NDA filing for the treatment of anaemia in chronic renal failure patients on dialysis in the second quarter. The prospectus accompanying the offering confirms this submission schedule.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC012316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel